CalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell?

CalciMedica Inc. (NASDAQ:CALC) traded down 2.1% during trading on Tuesday . The company traded as low as $5.55 and last traded at $5.73. 44,801 shares were traded during mid-day trading, a decline of 51% from the average session volume of 92,307 shares. The stock had previously closed at $5.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $16.00.

CalciMedica Stock Performance

The company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. The company has a market capitalization of $82.56 million, a price-to-earnings ratio of -3.54 and a beta of 0.58. The firm has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $3.24.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. On average, sell-side analysts anticipate that CalciMedica Inc. will post -2.21 EPS for the current fiscal year.

Institutional Trading of CalciMedica

Large investors have recently modified their holdings of the stock. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in CalciMedica in the third quarter valued at $165,000. Meritage Portfolio Management increased its holdings in CalciMedica by 33.8% during the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company’s stock worth $189,000 after purchasing an additional 15,539 shares during the period. Sheets Smith Investment Management acquired a new stake in CalciMedica in the 3rd quarter valued at about $157,000. Cetera Investment Advisers boosted its stake in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after buying an additional 9,045 shares during the period. Finally, Sound View Wealth Advisors Group LLC acquired a new position in shares of CalciMedica during the second quarter worth about $32,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.